Abstract
WHAT WE NEED TO KNOW: Is there an increased loss of elastic recoil over and above that due to ageing alone? How do we interpret inflammatory changes in the light of age-related airway inflammation? Is there an interaction between perception of airway narrowing and severity or control of disease? Are symptom-based action plans appropriate? Is control of the disease affected by the distribution of inhaled therapeutic aerosols and dry powder particles? WHAT WE NEED TO DO: Include patients aged 80 years and over in clinical trials. Assess functional and inflammatory parameters with appropriate age-matched controls in clinical trials. Assess feasibility and efficacy of symptom-based action plans versus those based on objective monitoring. Assess the responsiveness of elderly people to currently recommended therapies.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
